PTEN Gene Function
Phosphatase and Tensin Homolog
Overview
PTEN is the second most frequently mutated tumour suppressor after TP53, lost in ~30% of glioblastomas, endometrial, and prostate cancers. As the PIP3 phosphatase opposing PI3K, PTEN loss creates constitutive AKT/mTOR signalling equivalent to PI3K hyperactivation — but without a druggable mutant enzyme target. Germline PTEN mutations cause Cowden syndrome (~85% lifetime breast cancer risk, ~35% endometrial risk). AKT inhibitors (capivasertib, CAPItello-291) address PTEN loss more directly than isoform-selective PI3K inhibitors. Nuclear PTEN function independently maintains chromosomal stability through HR pathway support, suggesting HRD-like vulnerability in PTEN-null tumours.
Molecular Mechanism
Mechanism Summary
PTEN is the second most frequently mutated tumour suppressor after TP53, lost in ~30% of glioblastomas, endometrial, and prostate cancers. As the PIP3 phosphatase that directly opposes PI3K activity, PTEN loss is functionally equivalent to constitutive PI3K activation — but without a druggable mutant enzyme site that PIK3CA mutations provide. Nuclear PTEN independently maintains chromosomal stability through RAD51 retention at DSBs and APC complex regulation, providing a second layer of tumour suppression mechanistically distinct from its cytoplasmic lipid phosphatase function.
Step-by-Step Mechanism
PI3K (activated by RTKs or RAS) phosphorylates PIP2→PIP3 at the D3 position of the inositol ring, generating the second messenger PIP3 at the inner leaflet of the plasma membrane.
PTEN dephosphorylates PIP3→PIP2 via its phosphatase domain, reducing PIP3 concentration at the membrane and directly countering PI3K activity in real time.
Nuclear PTEN (imported via monoubiquitination by NEDD4-1) promotes RAD51 retention at DSBs, contributing to HR fidelity and chromosomal stability independent of lipid phosphatase function.
Upstream Regulators
E3 ligase that ubiquitinates PTEN for nuclear import and (at high expression) degradation
Bind and inhibit PTEN lipid phosphatase activity; recurrently mutated in melanoma
Ubiquitin ligase/DUB pair regulating PTEN stability
Downstream Targets
Reduces AKT membrane recruitment and activation
Attenuates protein synthesis, survival, and metabolism
Promotes HR fidelity; chromosomal stability
Key Post-Translational Modifications
Autoinhibited closed conformation; reduced membrane association
Nuclear import; stabilisation of HR at DSBs
Blocks active-site access; reduces lipid phosphatase activity
Disease Mechanism
PTEN is the second most commonly mutated tumour suppressor after TP53. Somatic loss occurs in ~30% of glioblastomas, prostate cancers, and endometrial cancers. Germline mutations cause Cowden syndrome (multiple hamartomas, high breast/thyroid/endometrial cancer risk). PTEN loss creates dependency on the PI3K/AKT pathway, rationalising study of pathway inhibitors. Therapeutic challenges specific to PTEN-deficient tumours: (1) PTEN loss eliminates a brake rather than activating a druggable enzyme; PI3Kα inhibitors have reduced single-agent efficacy in PTEN-null versus PIK3CA-mutant tumours because PIP3 can be generated by multiple p110 isoforms. (2) Capivasertib addresses pathway activation downstream; in the CAPItello-291 biomarker-altered population, median PFS was 7.3 months with capivasertib plus fulvestrant versus 3.1 months with placebo plus fulvestrant. (3) mTOR inhibitors show modest activity in PTEN-loss cancers but are limited by feedback AKT reactivation. (4) Nuclear PTEN loss is associated with genomic instability and is being studied as a possible marker of DNA-repair vulnerability.
Database References
Key Pathways
- ·PI3K-AKT-mTOR signaling
- ·PTEN regulation of PI3K pathway
- ·Homologous recombination (nuclear PTEN)
- ·Apoptosis
Disease Associations
- ·Cowden syndrome
- ·Glioblastoma
- ·Prostate cancer
- ·Endometrial cancer
- ·Triple-negative breast cancer
Research Activity
PTEN is an actively studied target: about 40+ clinical trials that mention it are currently recruiting on ClinicalTrials.gov. Trial activity reflects research interest, not proven benefit — designs, endpoints and populations vary widely.
Track PTEN trials
New and changed oncology trials, summarised in plain language each day.
Functional Partners
Common Questions About PTEN
What does PTEN do?
PTEN is a lipid phosphatase that dephosphorylates PIP3 back to PIP2, directly opposing PI3K kinase activity and suppressing the PI3K/AKT/mTOR signalling axis. This positions PTEN as the primary brake on the most commonly activated oncogenic pathway in human cancer.
In which cancers is PTEN lost?
PTEN is lost or mutated in approximately 30% of glioblastomas and prostate cancers, and frequently in endometrial, breast, and thyroid cancers. Germline PTEN mutations cause Cowden syndrome, predisposing to breast, thyroid, and endometrial cancers through a two-hit mechanism.
Is PTEN loss targetable with drugs?
Loss of PTEN results in constitutive AKT activation, creating selective dependency on the PI3K/mTOR pathway. PI3Kα inhibitors (alpelisib) and AKT inhibitors (capivasertib) are approved or in late trials for PTEN-loss tumours, though compensatory reactivation through receptor tyrosine kinases is a common resistance mechanism.
What is the relationship between PTEN and AKT?
PTEN and AKT are in direct functional opposition: PTEN removes PIP3, the lipid second messenger that recruits AKT to the plasma membrane for activation. PTEN loss therefore equals AKT hyperactivation, driving downstream mTORC1 activity that controls protein synthesis, metabolism, and cell survival.
How does PTEN loss differ from PIK3CA mutation in terms of PI3K pathway activation and druggability?
Both PTEN loss and PIK3CA activating mutations result in elevated PIP3 and constitutive AKT/mTOR signalling, but the therapeutic implications differ significantly. PIK3CA mutations create a hyperactive enzyme with an altered kinase domain that can be selectively inhibited by alpelisib (PI3Kα-selective). PTEN loss removes a phosphatase entirely — all PI3K isoforms (p110α, p110β, p110δ) now contribute unchecked PIP3 accumulation without a dominant druggable target. This means PI3Kα-selective inhibitors like alpelisib have reduced efficacy in PTEN-null tumours compared to PIK3CA-mutant tumours; pan-PI3K or AKT inhibitors (capivasertib) are more appropriate for PTEN-deficient disease.
What is Cowden syndrome and what cancer risks does PTEN germline mutation confer?
Cowden syndrome (PTEN hamartoma tumour syndrome) is an autosomal dominant disorder caused by germline PTEN mutations, characterised by multiple hamartomas (benign overgrowths) and dramatically elevated cancer risks: ~85% lifetime breast cancer risk, ~35% endometrial cancer risk, ~35% thyroid cancer risk, and elevated colorectal and renal cancer risks. The facial trichilemmomas, oral papillomatosis, and macrocephaly are pathognomonic physical findings that prompt genetic testing. Surveillance recommendations include annual mammography from age 25, annual thyroid ultrasound, and annual endometrial sampling from age 30–35.
Why is PTEN harder to target therapeutically than PIK3CA mutations?
The fundamental challenge is that PTEN is a tumour suppressor whose loss is the problem — you cannot inhibit an absent protein. The therapeutic approach must therefore target the downstream consequences of PTEN loss rather than PTEN itself. Strategies include: (1) AKT inhibitors (capivasertib) targeting the constitutive AKT activation downstream; (2) mTOR inhibitors (everolimus) for mTORC1-dependent growth; (3) pan-PI3K inhibitors that suppress all p110 isoforms contributing to PIP3 accumulation. All of these approaches face the feedback problem — mTORC1 inhibition relieves IRS-1 negative feedback and reactivates PI3K, creating compensatory AKT activation that limits efficacy.